Showing 2151-2160 of 2314 results for "".
- Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-trading-halted-today-fda-committee-meeting-to-discuss-teprotumumab-for-thyroid-eye-disease/2477167/Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss
- Stephen Hahn Confirmed as New FDA Chiefhttps://modernod.com/news/stephen-hahn-confirmed-as-new-fda-chief/2477168/The US Senate voted 72 to 18 on Thursday to confirm President Donald Trump nominee Stephen Hahn as the next FDA Commissioner. The radiation oncologist, who was recently cleared by the Senate Health, Education, Labor and Pensions Committee, replaces Scott Gottlieb, who stepped down in Ap
- Watching for Radiation Harm After Interventional Procedureshttps://modernod.com/news/watching-for-radiation-harm-after-interventional-procedures/2477165/Interventional procedures can expose interventionalists and nearby staff to high doses of radiation, and this can lead to radiation-associated lens opacities, said Madan Rehani, PhD, director of Global Outreach for Radiation Protection at Massachusetts General Hospital in Boston, in a Medscape
- Eylea Injection Prefilled Syringe Now Availablehttps://modernod.com/news/eylea-injection-prefilled-syringe-now-available/2477154/Regeneron announced that the Eylea (aflibercept) prefilled syringe is now available for doctors to order. The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer Eylea that requires fewer preparation steps compared to vials. Eylea is the
- Senate Panel Advances Trump’s Nominee for FDA Commissionerhttps://modernod.com/news/senate-panel-advances-trumps-nominee-for-fda-commissioner/2477137/A Senate panel on Tuesday advanced President Donald Trump’s nomination of Dr. Stephen Hahn to be the next Food and Drug Administration commissioner, according to a CNBC report. The
- New Funding for Orbis International Will Increase Global Access to Eye Care Through Technologyhttps://modernod.com/news/new-funding-for-orbis-international-will-increase-global-access-to-eye-care-through-technology/2477136/This Giving Tuesday, Orbis International announced the launch of its Silicon Valley Orbis Innovation Fund, which seeks to raise $8 million in donations to harness the next generation of technology that will revolutionize the future of e
- Eversight Awarded $50,000 to Investigate Cell Expansion to Address Global Cornea Shortagehttps://modernod.com/news/eversight-awarded-50000-to-investigate-cell-expansion-to-address-global-cornea-shortage/2477085/Eversight announced the Eye Bank Association of America (EBAA) awarded a $50,000 High Impact Research Grant to the organization and its research partners to investigate cell expansion aiming to mitigate the global shortage of surgical quality donor corneas available for transplantation. Mo
- Study: Eye Damage Linked to Over-the-Counter Vitamin That Lowers Cholesterol Can Be Reversedhttps://modernod.com/news/study-eye-damage-linked-to-over-the-counter-vitamin-that-lowers-cholesterol-can-be-reversed/2477051/In a first-of-its-kind clinical report, retina specialists at the New York Eye and Ear Infirmary of Mount Sinai (NYEE) have shown that severe vision loss from a self-prescribed high dose of over-the-counter niacin is linked to injury of a specific cell type in a patient’s eye. The experts report
- Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucomahttps://modernod.com/news/nicox-reports-positive-results-of-secondary-analyses-from-phase-2-trial-further-highlighting-potential-of-ncx-470-in-glaucoma/2477029/Nicox announced the results of secondary analyses of its Dolomites phase 2 trial with NCX 470 for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Positive topline results were
- Using AI to Screen for Diabetic Eye Disease Feasible in the Real Worldhttps://modernod.com/news/using-ai-to-screen-for-diabetic-eye-disease-feasible-in-the-real-world/2477017/New research shows that an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system doesn’t require the input of an expert ophthalmologist and it can provide a reading in 60 seconds, making real-time screening possible f